title: Multiple myeloma--translation of trial results into reality.
authors.affiliation: Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: rajkumar.vincent@mayo.edu.
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001896:Boron Compounds / Q000627:therapeutic use; D000069286:Bortezomib / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002986:Clinical Trials as Topic; D003497:Cyclic N-Oxides; D017277:Drug Approval; D055808:Drug Discovery; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007212:Indolizines; D007783:Lactones / Q000627:therapeutic use; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011726:Pyridinium Compounds; D011758:Pyrroles / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003497:Cyclic N-Oxides; D007212:Indolizines; D007783:Lactones; C554738:ONX 0912; D009842:Oligopeptides; D011726:Pyridinium Compounds; D011758:Pyrroles; C546027:elotuzumab; C553669:dinaciclib; C556306:daratumumab; D013792:Thalidomide; D000069286:Bortezomib; C475865:marizomib; C548400:ixazomib; D000077269:Lenalidomide; D005998:Glycine